drugset
drugset / Trial / NCT00499538

Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

NCT00499538 ↗

Phase 1 Completed 40 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-label

Summary

To evaluate the comparative bioavailability of 3 new tablet formulations of SKI-606 with a reference capsule and an oral solution in healthy subjects.

Timeline

Start
2007-07
Primary completion
—
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 500 mg Oral

Indications

No indication recorded.